Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Am J Med Sci. 2018 Oct 2;356(6):518–527. doi: 10.1016/j.amjms.2018.09.010

FIGURE 3.

FIGURE 3

Change in A1C with the iGlarLixi fixed ratio combination. Reproduced with permission from Rosenstock et al.61 Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial, American Diabetes Association, 2016. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. LS mean change in HbA1c. Data are mean ± SD. Abbreviations: iGlar, insulin glargine; iGlarLixi, insulin glargine/lixisenatide; LS, least squares; lixi, lixisenatide; mITT, modified intent-to-treat.